AtriCure Inc.  

(Public, NASDAQ:ATRC)   Watch this stock  
Find more results for ATRC
9.28
-0.02 (-0.22%)
May 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.20 - 9.45
52 week 5.90 - 9.98
Open 9.21
Vol / Avg. 16,142.00/68,064.00
Mkt cap 194.25M
P/E     -
Div/yield     -
EPS -0.46
Shares 20.93M
Beta 1.39
Inst. own 77%
Aug 2, 2013
Q2 2013 AtriCure, Inc. Earnings Release Add to calendar
May 23, 2013
AtriCure, Inc. Annual Shareholder Meeting
May 3, 2013
Q1 2013 AtriCure, Inc. Earnings Release
May 2, 2013
Q1 2013 AtriCure, Inc. Earnings Conference Call - Webcast
Feb 28, 2013
Q4 2012 AtriCure, Inc. Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -10.00% -10.73%
Operating margin -9.26% -10.25%
EBITD margin - -7.54%
Return on average assets -17.21% -22.73%
Return on average equity -30.50% -53.59%
Employees 230 -
Carbon Disclosure Rating - -

Address

6217 Centre Park Drive
WEST CHESTER, OH 45069
United States - Map
+1-513-7554100 (Phone)
+1-513-7554108 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

AtriCure, Inc., is a medical device company. The Company develops, manufactures and sells cardiac surgical ablation systems designed to create lesions, or scars, in cardiac, or heart, tissue and devices for the exclusion of the left atrial appendage. The Company has two primary product lines for the ablation of cardiac tissue. Its primary product line, which accounts for a majority of its revenues is the AtriCure Synergy Ablation System, a bipolar ablation clamp system and related radiofrequency ablation devices. It also offers a cryoablation product line, which features reusable and disposable cryoablation devices. In addition, it offers the AtriClip Gillinov-Cosgrove Left Atrial Appendage System, or AtriClip system, which is designed to exclude the left atrial appendage.

Officers and directors

Richard M. Johnston Independent Chairman of the Board
Age: 77
Bio & Compensation  - Reuters
Michael H. Carrel President, Chief Executive Officer, Director
Age: 42
Bio & Compensation  - Reuters
M. Andrew Wade Principal Financial Officer, Principal Accounting Officer
Age: 37
Bio & Compensation  - Reuters
Andrew L. Lux Ph.D. Chief Operating Officer, Vice President
Age: 60
Bio & Compensation  - Reuters
Patricia J. Kennedy Vice President, General Manager - International
Age: 51
Bio & Compensation  - Reuters
Michael Rogge Vice President - Marketing
Bio & Compensation  - Reuters
Stewart W. Strong Vice President - Global Marketing
Age: 45
Bio & Compensation  - Reuters
James L. Lucky Vice President - Regulatory Affairs and Quality Systems
Age: 50
Bio & Compensation  - Reuters
Michael D. Hooven Director
Age: 56
Bio & Compensation  - Reuters
Mark A. Collar Independent Director
Age: 59
Bio & Compensation  - Reuters